Navigation Links
New Phase III Data Presented for Once Monthly Dosing Regimen of Risedronate to Treat Postmenopausal Osteoporosis
Date:9/19/2007

nts around the globe. It is a collaboration between Procter & Gamble Pharmaceuticals and sanofi-aventis U.S.

About Procter & Gamble (NYSE: PG)

Three billion times a day, P&G brands touch the lives of people around the world. The company has one of the strongest portfolios of trusted, quality, leadership brands, including Pampers(R), Tide(R), Ariel(R), Always(R), Whisper(R), Pantene(R), Mach3(R), Bounty(R), Dawn(R), Gain(R), Pringles(R), Folgers(R), Charmin(R), Downy(R), Lenor(R), Iams(R), Crest(R), Oral-B(R), Actonel(R), Duracell(R), Olay(R), Head & Shoulders(R), Wella(R), Gillette(R), and Braun(R). The P&G community consists of 138,000 employees working in over 80 countries worldwide. Please visit http://www.pg.com for the latest news and in-depth information about P&G and its brands.

About sanofi-aventis

Sanofi-aventis is one of the world leaders in the pharmaceutical industry, ranking number one in Europe. Backed by a world-class R&D organization, sanofi-aventis is developing leading positions in seven major therapeutic areas: cardiovascular, thrombosis, oncology, metabolic diseases, central nervous system, internal medicine and vaccines. Sanofi-aventis is listed in Paris (EURONEXT: SAN) and in New York (NYSE: SNY).

For P&G: All statements, other than statements of historical fact included in this release, are forward-looking statements, as that term is defined in the Private Securities Litigation Reform Act of 1995. Such statements are based on financial data, market assumptions and business plans available only as of the time the statements are made, which may become out of date or incomplete. We assume no obligation to update any forward-looking
'/>"/>

SOURCE The Alliance for Better Bone Health
Copyright©2007 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6

Related medicine technology :

1. Data Available From Erbitux Phase III Study in First-Line Treatment of Advanced Lung Cancer
2. Phase 3 Results for Dabigatran Etexilate, an Investigational Oral Anticoagulant, Presented Today at the XXIst Congress of the International Society on Thrombosis and Haemostasis
3. YM BioSciences Announces Secondary Efficacy and Safety Findings in Randomized Phase IIB Aerolef Trial
4. Portola Pharmaceuticals Announces Positive Data from a Phase II Study of its Factor Xa Inhibitor at the XXI Congress of the International Society on Thrombosis and Haemostasis
5. Manhattan Pharmaceuticals Announces Results of Phase 2a Studies for Oral Oleoyl-estrone
6. Actemra (tocilizumab) Third Phase III Study Results Show Significant Improvement in Symptoms of Patients with Rheumatoid Arthritis
7. AVI BioPharma Partner Cook Medical Announces Completion of Patient Enrollment for APPRAISAL Phase II Clinical Trial for Treatment of Cardiovascular Disease
8. NexMed Announces Completion of Patient Enrollment in Two Pivotal Phase 3 Studies for Anti-Fungal Product
9. AM-Pharma Announces Positive Results of Phase IIa Clinical Trial with Alkaline Phosphatase For Ulcerative Colitis
10. Phase III Trial Results Show Superiority of Rivaroxaban over Enoxaparin for the Prevention of Venous Thromboembolism in Patients Undergoing Knee Replacement Surgery
11. Phase III Trial Results Show Superiority of Rivaroxaban over Enoxaparin for the Prevention of Venous Thromboembolism in Patients Undergoing Knee Replacement Surgery
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/15/2008)...reflects depth and breadth of, collaboration with... for diverse forms of cance...a(R), the leading IV, bisphosphonate, on relapse r... Four oral sessions to feature RAD001, first oral ...g first results of RECORD-1 study in renal cell ...
(Date:5/15/2008)...-FirstCall/ -- Sanofi-aventis,(EURONEXT: SAN and N...andmark ATHENA study showed Multaq(R) (dronedarone...ts with atrial fibrillation or atrial flutter,dec... or death from any,cause by a statistically signif...y endpoint. The ATHENA results will be presented a...
(Date:5/15/2008)...swire/ -- Ergonex Pharma today,announced that the ...as,granted orphan drug designation to Terguride fo... (PAH). Terguride is currently being evaluated for... FDA,s grant of orphan drug designation to Terguri...ent program by offering regulatory,clinical devel...
(Date:5/15/2008)...rstCall/ -- Novavax, Inc. (Nasdaq:,NVAX) today ann...se I/IIa,study of its pandemic influenza vaccine i...vorable interim results from the first phase of th...thy adult volunteers, were,reported in December 20...e,is well tolerated and immunogenic at the 15 micr...
Breaking Medicine Technology:Strength and Innovation of Novartis Oncology Products and Pipeline With Potential to Improve Patient Treatment Demonstrated by More Than 170 Abstracts at ASCO Annual Meeting 2Strength and Innovation of Novartis Oncology Products and Pipeline With Potential to Improve Patient Treatment Demonstrated by More Than 170 Abstracts at ASCO Annual Meeting 3Strength and Innovation of Novartis Oncology Products and Pipeline With Potential to Improve Patient Treatment Demonstrated by More Than 170 Abstracts at ASCO Annual Meeting 4Strength and Innovation of Novartis Oncology Products and Pipeline With Potential to Improve Patient Treatment Demonstrated by More Than 170 Abstracts at ASCO Annual Meeting 5Strength and Innovation of Novartis Oncology Products and Pipeline With Potential to Improve Patient Treatment Demonstrated by More Than 170 Abstracts at ASCO Annual Meeting 6Strength and Innovation of Novartis Oncology Products and Pipeline With Potential to Improve Patient Treatment Demonstrated by More Than 170 Abstracts at ASCO Annual Meeting 7Strength and Innovation of Novartis Oncology Products and Pipeline With Potential to Improve Patient Treatment Demonstrated by More Than 170 Abstracts at ASCO Annual Meeting 8Strength and Innovation of Novartis Oncology Products and Pipeline With Potential to Improve Patient Treatment Demonstrated by More Than 170 Abstracts at ASCO Annual Meeting 9Strength and Innovation of Novartis Oncology Products and Pipeline With Potential to Improve Patient Treatment Demonstrated by More Than 170 Abstracts at ASCO Annual Meeting 10Landmark ATHENA Study Findings With Multaq(R) (dronedarone) Shows 24% Reduction In Cardiovascular Hospitalization or Death in Patients With Atrial Fibrillation 2Landmark ATHENA Study Findings With Multaq(R) (dronedarone) Shows 24% Reduction In Cardiovascular Hospitalization or Death in Patients With Atrial Fibrillation 3Landmark ATHENA Study Findings With Multaq(R) (dronedarone) Shows 24% Reduction In Cardiovascular Hospitalization or Death in Patients With Atrial Fibrillation 4Landmark ATHENA Study Findings With Multaq(R) (dronedarone) Shows 24% Reduction In Cardiovascular Hospitalization or Death in Patients With Atrial Fibrillation 5Landmark ATHENA Study Findings With Multaq(R) (dronedarone) Shows 24% Reduction In Cardiovascular Hospitalization or Death in Patients With Atrial Fibrillation 6Landmark ATHENA Study Findings With Multaq(R) (dronedarone) Shows 24% Reduction In Cardiovascular Hospitalization or Death in Patients With Atrial Fibrillation 7Terguride Receives FDA Orphan Drug Designation for the Treatment of Pulmonary Arterial Hypertension 2Novavax Completes Enrollment in Phase I/IIa Pandemic Influenza Vaccine Clinical Trial 2Novavax Completes Enrollment in Phase I/IIa Pandemic Influenza Vaccine Clinical Trial 3Massive necrosis after trans catheter treatment is more common in the presence of tumor capsule 6849 1Saline Irrigation Eases Chronic Nasal Symptoms 6846 1Saline Irrigation Eases Chronic Nasal Symptoms 6846 2deCODE genetics to Webcast Presentation at Piper Jaffray Annual Healthcare Conference 6842 1Healthcare Technologies Reports 2007 Nine Months 26 Third Quarter Results 1926 1Healthcare Technologies Reports 2007 Nine Months 26 Third Quarter Results 1926 2Healthcare Technologies Reports 2007 Nine Months 26 Third Quarter Results 1926 3
...-FirstCall/ --,Advanced Magnetics today announced ...nical trials of ferumoxytol as an,intravenous (IV)...nted today at approximately 6:00 pm EDT as posters...al Meeting in Orlando,Florida. These posters are ... web site at <a target="_blank" href=,"http://www....
.../PRNewswire-FirstCall/ -- Sunesis Pharmaceuticals,...t data at the Annual Meeting,of the American Assoc... 14-18, 2007 in Los Angeles, California. , Data be...n-clinical data on SNS-032, a highly selective and...s) 2, 7 and 9 that is,currently in a Phase 1 clini...
Other Medicine Technology:Advanced Magnetics Announces Positive Results from Two Additional,Phase III Studies of Ferumoxytol as an Intravenous Iron Replacement,Therapeutic 2Advanced Magnetics Announces Positive Results from Two Additional,Phase III Studies of Ferumoxytol as an Intravenous Iron Replacement,Therapeutic 3Advanced Magnetics Announces Positive Results from Two Additional,Phase III Studies of Ferumoxytol as an Intravenous Iron Replacement,Therapeutic 4Advanced Magnetics Announces Positive Results from Two Additional,Phase III Studies of Ferumoxytol as an Intravenous Iron Replacement,Therapeutic 5Advanced Magnetics Announces Positive Results from Two Additional,Phase III Studies of Ferumoxytol as an Intravenous Iron Replacement,Therapeutic 6Advanced Magnetics Announces Positive Results from Two Additional,Phase III Studies of Ferumoxytol as an Intravenous Iron Replacement,Therapeutic 7Advanced Magnetics Announces Positive Results from Two Additional,Phase III Studies of Ferumoxytol as an Intravenous Iron Replacement,Therapeutic 8Sunesis Pharmaceuticals to Present Data at the Annual Meeting of,the American Association for Cancer Research 2
(Date:5/16/2008)... sufferers gain benefit from calcitriol, an oral f...-- Taking activated vitamin D may cut the risk of ...idney disease by about one quarter, a new study su... 1,400 patients, those being treated with calcitri... overall risk of death lowered by 26 percent when ...
(Date:5/16/2008)...vices for Frail Seniors and People With,Disabiliti...e/ -- Thousands of,homecare workers across the sta...oposed cuts to hours of service, wages and benefit...nerable workers and the,people they serve deeper i...ices for seniors and people with disabilities from...
(Date:5/16/2008)...ment for National HIV Vaccine Awareness Day, May,1...Twenty-six years into the,AIDS epidemic, someone i...U.S. On Sunday, May 18, HIV Vaccine Awareness Day,... National Institute of Allergy and Infectious,Dise...ive, urges everyone,to help end the AIDS epidemic ...
(Date:5/16/2008)...ire/ -- Huntsworth plc (LSE: HNT), "the Group",a ...are communications,group headquartered in London, ...t to the Group,s performance in the first quarter ...tatement follows below., 15 May 2008, ... Interim Management Statement, Re...
Breaking Medicine News(10 mins):Health News:Vitamin D Use Linked to Lower Mortality in Kidney Patients 2Health News:Homecare Workers Outraged by Proposed Cuts, Wage Reductions 2Health News:AIDS Action Urges Everyone to Help End the AIDS Epidemic by Being Part of the Search for an HIV Vaccine 2Health News:Huntsworth plc Releases Interim Statement on First Quarter 2008 2Health News:Huntsworth plc Releases Interim Statement on First Quarter 2008 3Health News:Huntsworth plc Releases Interim Statement on First Quarter 2008 4
... study has revealed that the fertility technique -...n hyperstimulation – is only as effective as tryin...les. The results of the study have been published...ch was conducted on 253 couples with unexplained i...
...P Leader of three years, Carole James, 48, faces s... localized cancer of the lining of the uterus.// ...al checkup earlier in the week with biopsy confirm...r, that has a recovery rate of 80 to 90 per cent. ...
...with type-1 diabetes are more prone to develop mul... people, a Denmark study reveals.// Both type-1 d... body builds up an aberrant immune response agains...cells in patients with diabetes, and the myelin sh...
...ents have been urged to invest more money in menta...nts and the services offered.// Although the new...4 billion over four years, it still fell short of ... said John Mendoza, the chief executive officer of...
Other Medicine News:
Micro instruments designed to provide maximum grasping, resecting capability, and excellent maneuverability for easy access to tight, small joints (wrist, elbow, and ankle).,Features pinless hinge d
Micro instruments designed to provide maximum grasping, resecting capability, and excellent maneuverability for easy access to tight, small joints (wrist, elbow, and ankle).,Features pinless hinge d
Made exclusively from LactoSorb Resorbable Copolymer.
The Stryker Cross-Screw System offers the surgeon a simple and secure method for ACL reconstruction utilizing soft tissue grafts. The Stryker Cross-Screw System provides the latest technology in femo
Medicine Products: